QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SMMT

QT47Summit Therapeutics Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
13.75
-0.32-2.27%
OverviewShort InterestFilings
SMMTQT47Summit Therapeutics Inc.·NASDAQ
OverviewShort InterestFilings
13.75-2.27%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
0.09
Insider Own-
Shs Outstand776.16M
Perf Week5.12%
Market Cap10.91BForward P/E-EPS next Y-1.13Insider Trans1.01%Shs Float-Perf Month-13.25%
Enterprise Value10.84BPEG0.07EPS next Q-0.26Inst Own-Short Float-Perf Quarter-12.53%
Income-1052766568.00P/S0.00EPS this Y-1354.37%Inst Trans-Short Ratio-Perf Half Y-20.20%
Sales-P/B26.35EPS next Y0.02%ROA-214.23%Short Interest-Perf YTD-21.38%
Book/sh0.53P/C-EPS next 5Y-ROE-340.55%52W High30.98 -55.62%Perf Year-30.73%
Cash/sh0.58P/FCF-EPS past 3/5Y-ROIC-248.14%52W Low12.55 9.56%Perf 3Y-
Dividend Est.-EV/EBITDA-10.29Sales past 3/5Y-Gross Margin0.00%Volatility4.14% 5.45%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-540.00%Oper. Margin0.00%ATR (14)1.11Perf 10Y-
Dividend Ex-Date-Quick Ratio7.41Sales Y/Y TTM-Profit Margin0.00%RSI (14)37.16Recom2.80
Dividend Gr. 3/5Y-Current Ratio7.41EPS Q/Q-166.67%SMA20-9.25%Beta1.75Target Price19.50
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA50-24.00%Rel Volume1.57Prev Close14.07
Employees159LT Debt/Eq0.03EarningsAug 10SMA200-23.44%Avg Volume5.56MPrice13.75
IPO DateMar 05, 2015Option/ShortYes / YesEPS/Sales Surpr.27.27% -Net Debt/EBITDA0.06Volume8,716,641Change-2.27%
Analyst Ratings
DateActionAnalystRatingTarget
May-22-26DowngradeHC Wainwright & Co.Buy → Neutral
May-04-26ReiteratedH.C. WainwrightBuy$30 → $23
May-01-26ReiteratedPiper SandlerNeutral$40 → $16
Mar-16-26DowngradeJefferiesBuy → Hold
Feb-24-26ReiteratedH.C. WainwrightBuy$40 → $30
Jan-14-26ReiteratedPiper Sandler$40
Dec-17-25ReiteratedSummit Redstone Partners$13 → $18
Dec-17-25UpgradeBarclaysUnderweight → Equal Weight
Oct-21-25ReiteratedH.C. WainwrightBuy$44 → $40
Oct-21-25ReiteratedBarclaysUnderweight$16
Latest News
Jun-15-26
Jun-15-2601:35PM
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through ItSeekingAlpha
Jun-11-26
Jun-11-2607:55AM
Summit Therapeutics Withdraws Previously Announced Proposed $500M Underwritten Public Offering Of Shares Due To Market ConditionsBenzinga
07:55AM
Summit Therapeutics Withdraws Previously Announced Proposed $500M Underwritten Public Offering Of Shares Due To Market ConditionsBenzinga
Jun-10-26
Jun-10-2601:13PM
Oil Jumps On Iran Strikes, Nasdaq 100 Falls On Hot Inflation: Stock Market TodayBenzinga
08:03AM
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
1/31/2019
Total Revenue5700
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit5700
Selling, General and Administrative Excl. Other1455748
Research and Development38538132
Other Operating Expense2-11
Operating Income22-1,094-181
Interest Expense009
Unusual Expense
———
Non-Operating Income (Expense)0-15-12
Net Income Before Taxes13-1,080-177
Income Taxes-300
Consolidated Net Income7-1,080-177
Net Income From Continuing Operations15-1,080-177
Net Income7-1,080-177
EPS (Recurring)0.09-1.44-0.25
EPS (Basic, Before Extraordinaries)0.09-1.44-0.25
EPS (Diluted)0.09-1.44-0.25
EBITDA-2-1,079-168
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
152.78——
Price To Sales Ratio
36.91——
Gross Margin100.00——
Operating Margin38.60——
Net Margin12.28——
Shares Outstanding153748714
Market Capitalization2,10413,083—
Operating Lease Expense
———
Insider Trading Volume
$14.39$13.00$11.61$10.22$8.83● Close Price0.00M25.90M51.81M77.71M103.62MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zanganeh MahkamCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04 12:00 AM
Soni Manmeet SinghCOO and CFOJun 04 '26Buy14.4550,000722,2503,123,603Jun 04 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04 12:00 AM
Xia YuDirectorOct 21 '25Buy18.74533,6179,999,98332,057,147Oct 23 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11 12:00 AM
DUGGAN ROBERT WCo-Chief Executive OfficerMay 30 '25Option Exercise2.64149,090393,598555,754,696Jun 02 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerMay 30 '25Option Exercise2.64149,090393,598555,754,696Jun 02 12:00 AM
Zanganeh MahkamCo-Chief Executive OfficerApr 08 '25Option Exercise1.587,970,11012,592,774555,680,151Apr 09 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR